Please login to the form below

Not currently logged in
Email:
Password:

Gazyvaro

This page shows the latest Gazyvaro news and features for those working in and with pharma, biotech and healthcare.

Roche and AbbVie prepare to move Venclexta into first-line CLL

Roche and AbbVie prepare to move Venclexta into first-line CLL

Venclexta (venetoclax) given in combination with Roche’s anti-CD20 drug Gazyva/Gazyvaro (obinutuzumab) has been shown to extend progression-free survival (PFS) compared to Gazyva plus chlorambucil chemotherapy – already approved ... CLL14 is the

Latest news

More from news
Approximately 12 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics